News

The vascular endothelial growth factor (VEGF) Trap is a member of Regeneron’s proprietary family of “Trap” product candidates. Regeneron has developed patented methods of designing potential therapeutic molecules,

Recently, a team of researchers in the UK set out to test the effectiveness of anti-TNF-alpha therapy on a small sample of patients with very early, poor-prognosis, previously

Aptamera’s principal asset is AGRO100, a novel aptamer drug that has shown promising anticancer effects and a marked lack of side effects in a phase I trial of

There is no change in the US arrangement under which GSK and Bayer (through its distributor Schering-Plough) now co-promote Levitra (vardenafil HCl). Similarly, there will be no change

Clinical trials have demonstrated that adult growth hormone deficiency (AGHD) can be effectively treated with Saizen (somatropin, rDNA origin, for injection). With the US approval, the treatment is

Abraxane is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should

Bonefos (clodronate) is an oral non-amino bisphosphonate intended to reduce the occurrence of bone metastases in the post-surgical (adjuvant) treatment of breast cancer patients. Berlex, Schering’s US affiliate,

The company intends to ship product to the US and initiate enrollment of subjects before the end of January 2005. The Fluviral vaccine to be tested was produced

Enrollment in Inhibitex’ ongoing phase III clinical trial of Veronate for the prevention of hospital-associated infections in very low birth weight infants has outpaced the company’s initial expectations